Entrada Therapeutics (TRDA) Stock: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$5.38
-0.30 (-5.28%)
▼
5d:
-12.66%
30d:
-26.3%
90d:
-28.55%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TRDA is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TRDA is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $5.38, which is considered oversold relative to its 30-day fair value range of $6.24 to $7.26.
Technical Outlook: Technically, TRDA is showing sideways momentum. Immediate support is located at $5.17, while resistance sits at $6.93. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: TRDA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.00 (+253.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TRDA is showing sideways momentum. Immediate support is located at $5.17, while resistance sits at $6.93. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: TRDA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.00 (+253.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.24 -
$7.26
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.3%)
- BULLISH: Trading 253.2% below Wall St target ($19.00)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.24 -
$7.26
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.17
Resistance Level
$6.93
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.79
Wall Street Target
$19.00
(+253.2%)
Revenue Growth (YoY)
-53.9%
Share & Embed Analysis
Last updated: October 03, 2026 2:32 AM ET
Data refreshes hourly during market hours. Next update: 3:32 AM
Data refreshes hourly during market hours. Next update: 3:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |